KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jun 16, 2026 >>  ABB India 7019  [ 1.35% ]  ACC 1348.45  [ -0.68% ]  Ambuja Cements 426.2  [ -0.54% ]  Asian Paints 2747.5  [ 0.30% ]  Axis Bank 1365.6  [ -0.19% ]  Bajaj Auto 9934.1  [ -0.09% ]  Bank of Baroda 275.3  [ -0.22% ]  Bharti Airtel 1858.05  [ 0.93% ]  Bharat Heavy 384.15  [ 0.33% ]  Bharat Petroleum 311.8  [ 0.45% ]  Britannia Industries 5222.25  [ 0.49% ]  Cipla 1372.75  [ -0.63% ]  Coal India 451  [ 1.38% ]  Colgate Palm 2097.1  [ 1.88% ]  Dabur India 435.7  [ 1.54% ]  DLF 629.7  [ 2.72% ]  Dr. Reddy's Lab. 1277.85  [ -0.11% ]  GAIL (India) 175.75  [ 0.14% ]  Grasim Industries 3137.85  [ -0.73% ]  HCL Technologies 1159.35  [ 3.59% ]  HDFC Bank 784.7  [ 0.96% ]  Hero MotoCorp 5028.2  [ 0.11% ]  Hindustan Unilever 2201.15  [ 2.10% ]  Hindalco Industries 982.4  [ -3.04% ]  ICICI Bank 1334.9  [ 0.54% ]  Indian Hotels Co. 694.3  [ 0.64% ]  IndusInd Bank 925.75  [ -0.79% ]  Infosys 1143.3  [ 0.71% ]  ITC 291.75  [ 1.32% ]  Jindal Steel 1139.1  [ -0.92% ]  Kotak Mahindra Bank 408.1  [ 0.60% ]  L&T 4185.7  [ 0.34% ]  Lupin 2270.1  [ -0.15% ]  Mahi. & Mahi 3137.8  [ 0.09% ]  Maruti Suzuki India 13692.85  [ -0.81% ]  MTNL 31.27  [ 0.48% ]  Nestle India 1391.9  [ 1.27% ]  NIIT 106.32  [ 19.13% ]  NMDC 88.07  [ -0.42% ]  NTPC 355.45  [ 2.10% ]  ONGC 248.25  [ 1.87% ]  Punj. NationlBak 107.95  [ 0.05% ]  Power Grid Corpn. 285.65  [ 0.02% ]  Reliance Industries 1327.85  [ 1.59% ]  SBI 1015.5  [ -0.49% ]  Vedanta 300  [ -0.86% ]  Shipping Corpn. 308.45  [ -0.79% ]  Sun Pharmaceutical 1800.65  [ -0.32% ]  Tata Chemicals 729.6  [ -0.77% ]  Tata Consumer 1129.45  [ 2.64% ]  Tata Motors Passenge 393.6  [ -0.82% ]  Tata Steel 196  [ -0.71% ]  Tata Power Co. 402.1  [ -0.45% ]  Tata Consult. Serv. 2198.85  [ 1.72% ]  Tech Mahindra 1446.1  [ 1.45% ]  UltraTech Cement 11380  [ -0.82% ]  United Spirits 1300  [ 2.27% ]  Wipro 182.7  [ 0.72% ]  Zee Entertainment 111.29  [ 2.48% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    ALEMBIC PHARMACEUTICALS LTD.

    16 June 2026 | 12:00

    Industry >> Pharmaceuticals

    Select Another Company

    ISIN No INE901L01018 BSE Code / NSE Code 533573 / APLLTD Book Value (Rs.) 288.70 Face Value 2.00
    Bookclosure 29/07/2025 52Week High 1108 EPS 34.33 P/E 21.72
    Market Cap. 14657.71 Cr. 52Week Low 636 P/BV / Div Yield (%) 2.58 / 1.61 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011.

    2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr).

    Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA.

    2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.

    2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.".

    2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis

    2016 - Alembic Pharma inks JV agreement with Orbicular Pharma

    2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories.

    2018 -Alembic Pharma gets USFDA nod for ophthalmic solution. -Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain. -Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder. -Alembic Pharma gets tentative USFDA nod for ophthalmic solution. -Alembic bags approval for Bupropion Hydrochloride Tablets.

    2019 -Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution. -Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug. - Alembic Pharma gets USFDA nod for intraocular pressure reduction drug. -Alembic Pharma gets USFDA nod for glaucoma treatment drug.

    2020 -Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets. -Alembic Pharma gets final USFDA nod for eye drops solution. -Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets. -Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression. -Alembic Pharma gets final USFDA nod for Fenofibrate tablets.

    2021 -Alembic receives USFDA tentative approval for Selexipag Tablets. -Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. -Alembic Pharma gets USFDA nod for cancer treatment drug. -Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP.

    2022 -Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. -Alembic Pharma gets USFDA nod for Entacapone tablets. -Alembic Pharmaceuticals gets US FDA nod for antibiotic drug.

    2023 -Alembic has a cumulative total of 182 ANDA approvals from USFDA.

    2024 -Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. -Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. - Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg

    2025 -Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). -Alembic Pharmaceuticals Ltd has received final approval from the USFDA for its generic version of Sumatriptan Injection. -Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Carbamazepine extended-release tablets. - Alembic Pharmaceuticals Ltd. has received USFDA Final Approval for Ticagrelor Tablets, 60 mg. -Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg.

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 | Research Analyst: SEBI Regn No. INH200008705 | PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.